Form 4: REGENXBIO CEO Kenneth T. Mills Executes Stock Option and Sells Shares

REGENXBIO's CEO, Kenneth T. Mills, exercised stock options and sold 15,000 shares of common stock on April 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 15, 2024, Kenneth T. Mills, the President and CEO of REGENXBIO Inc., executed a stock option to acquire 15,000 shares of common stock at a price of $3.76 per share.
• Simultaneously, Mills sold 15,000 shares of REGENXBIO common stock at a weighted average price of $18.1914, with prices ranging from $17.82 to $18.61.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Mills directly owns 408,035 shares of REGENXBIO common stock.
• Mills also holds options to purchase 96,354 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports factual transactions. The use of a 10b5-1 plan suggests pre-planned activity, reducing potential negative interpretations.

Positives

• The CEO's transactions are being conducted under a pre-arranged Rule 10b5-1 trading plan, which can reassure investors that the sales are not based on insider information.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• While the Rule 10b5-1 plan mitigates some concerns, significant insider selling could still create short-term downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but it indicates ongoing stock option exercises and sales under a pre-arranged plan.

Industry Context

Insider transactions are common in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to avoid insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Comparing the CEO's transactions to those of executives at similar gene therapy companies like BioMarin, Sarepta Therapeutics, and bluebird bio could provide context.
• Analyzing the frequency and size of insider transactions at these companies, as well as their stock performance following such transactions, could offer a benchmark for evaluating the significance of Mills' actions.
• For example, if other CEOs in the sector are also exercising options and selling shares, it might suggest a broader trend related to executive compensation or market conditions.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, although the pre-arranged plan should mitigate concerns.
• The transactions could have a minor impact on the stock's liquidity and trading volume.

Key Dates